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1001-291 Treatment With Diclofenac, Rofecoxib and Celecoxib 
Is Associated With Increased Risk of Sudden Cardiac 
Arrest: A Nationwide Case-Crossover Study
Fredrik Folke, Emil L. Fosbøl, Peter Weeke, Lars Køber, Christian Torp-Pedersen, 
Gunnar H. Gislason, Department of Cardiology, Gentofte University Hospital, Denmark, 
Hellerup, Denmark, Department of Cardiology, The Heart Centre, University Hospital of 
Copenhagen, Rigshospitalet, Copenhagen, Denmark
Background: Selective cyclooxygenase-2 (COX-2) inhibitors and some non-steroidal 
anti-inﬂammatory drugs (NSAIDs) have been associated with increased cardiovascular 
risk. We studied prior NSAID use among patients experiencing sudden cardiac death on 
a national level.
Methods: We included 13051 patients experiencing out-of-hospital cardiac arrests in the 
nationwide Danish Cardiac Arrest Register from 2001-2004. By individual-level-linkage 
of nationwide administrative registries of drug dispensing from pharmacies in Denmark, 
prior use of all NSAIDs was identiﬁed. Risk of sudden cardiac arrest according to current 
NSAID treatment was analyzed by conditional logistic regression in case-crossover 
models. Current use was deﬁned as NSAID treatment 30 days prior to event.
Results: Any NSAID use 30 days prior to event was identiﬁed in 4954 patients (38.0%); 
2204 ibuprofen (16.9%), 1141 diclofenac (8.7%), 690 rofecoxib (5.3%), 688 celecoxib 
(5.3%), and 231 naproxen (1.8%). There was signiﬁcant increased risk of sudden cardiac 
arrest associated with current use of diclofenac, celecoxib, and rofecoxib, with a dose-
dependent increase in risk, whereas use of ibuprofen and naproxen was not associated 
with increased risk (Fig).
Conclusions: Current use of diclofenac and the selective COX-2 inhibitors rofecoxib and 
celecoxib is associated with increased risk of sudden cardiac arrest. Caution in use of 
NSAIDs is recommended and further studies of cardiovascular safety of NSAIDs are 
warranted. 
9:30 a.m.
1001-292 Primary Angioplasty Versus Fibrinolysis in Acute 
Myocardial Infarction: Long-Term Follow-Up in the 
DANAMI-2 Trial
Peter H. Nielsen, Michael Maeng, Martin Busk, Leif S. Mortensen, Torsten T. Nielsen, 
Henning R. Andersen, The DANAMI-2 Investigators, Department of Cardiology, Aarhus 
University Hospital, Skejby, Aarhus N, Denmark, UNI-C, Aarhus N, Denmark
Background: Based on a composite endpoint of death, re-infarction and stroke after 30 
days, the DANAMI-2 study concluded that a strategy of inter-hospital transfer for primary 
angioplasty (pPCI) was superior to on-site ﬁbrinolysis (FL) in the treatment of ST-elevation 
myocardial infarction (STEMI). In this study we investigated whether the non-signiﬁcant 
result on death was sustained at up to 10 years follow-up.
Methods: We randomly assigned 1,572 patients with STEMI to pPCI or accelerated 
treatment with intravenous alteplase; 1,129 patients were enrolled at 24 referral hospitals 
and 443 at 5 interventional centers. For the ﬁrst three years of follow-up causes of death 
was determined by an endpoint committee and beyond three years by the use of Danish 
registries.
Results: Eight patients emigrated and were followed until time of emigration. The 
remaining 1,564 patients had complete follow-up. Median follow-up time for all 1,572 
patients was 7.8 years. At the end of follow-up 442 (28.1%) patients had died, 26.5% in 
the pPCI group and 29.8% in the FL group (Longrank P=0.14). Cardiac death was 12.3% 
in the pPCI group and 15.3% in the FL group (Logrank P=0.09). Cause of death could not 
be determined in 25 patients.
Conclusion: Our study represents the longest follow-up period in the largest randomized 
comparison of pPCI and FL. It shows no signiﬁcant difference in total and cardiac 
mortality between the two groups. The curves for mortality do not intersect at any point 
during follow-up. 
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1001-289 Large Platelets Exhibit Greater in Vitro Activation and 
Decreased Inhibition With Aspirin Compared to Small 
Platelets
Kiran Kumar R. Mangalpally, Alan Siqueiros-Garcia, Muthiah Vaduganathan, Eli Lev, Jing-
Fei Dong, Neal S. Kleiman, Sasidhar Guthikonda, The Methodist Hospital, Houston, TX
Background: Increased mean platelet volume is associated with adverse cardiovascular 
outcomes, though the mechanisms for this are unclear. Larger platelets are possibly more 
active than smaller platelets, and could be resistant to the inhibitory effects of aspirin. 
We studied in vitro, the activation properties and inhibitory effects of aspirin on platelet 
fractions stratiﬁed according to size.
Methods: Flow cytometric separation of the largest and smallest quintiles of platelets 
based on forward scatter was performed on platelet-rich plasma from 9 healthy subjects. 
Separated platelets were stimulated with 10 μM ADP and 75 μM arachidonic acid (AA). 
Surface expression of alpha-granule contents (P-selectin, vWF and ﬁbrinogen), activated 
GPIIbIIIa and dense-granules were assessed with ﬂow cytometry. Platelet activation was 
measured before and after 265 μM aspirin in vitro.
Results: A greater % of large platelets exhibit surface expression of alpha-granule 
proteins and activated GPIIbIIIa in response to all agonists, compared to small platelets 
(Table). With in vitro aspirin, large platelets were inhibited to a lesser extent and remained 
signiﬁcantly more active than small platelets. A greater % of larger platelets stained for 
dense-granules than small platelets (54.5±15.3% vs. 25.6±6.8%, p<0.001).
Conclusions: More large platelets express activation molecules than small platelets 
upon stimulation. In vitro aspirin does not inhibit large platelets to the same degree as 
small platelets. 
Table I: Percentage of small and large platelets expressing alpha-
granule proteins and activated GPIIbIIIa after stimulation with ADP 
and AA, before and after in vitro aspirin (ASA).
ADP 10μM 75 μM AA - Pre-ASA 75 μM AA - Post ASA
P-value 
for AA:
Pre. Vs. 
Post ASA
Small Large P Small Large P Small Large P Small Large
Fibrinogen 16.5±13.2 38.8±12.4 0.001 25.5±16.3 66.2±8.8 <0.001 17.3±13.2 47.9±12.6 <0.001 0.01 0.001
vWF 35.9±24.3 73.9 ± 8.7 <0.001 29 ± 14.9 72.6±20.3 <0.001 12.5 ± 11 65 ± 21.1 0.001 0.01 0.2
P-selectin 25.2±10.1 47.1±14.5 0.001 20.9 ± 6.8 56.5±21.9 0.001 11.9 ± 6.1 56.9 ± 16 <0.001 0.01 0.48
GP IIb-IIIa 25±16.8 63.1±20 <0.001 11.3 ± 6 25.4±12.2 0.003 10.5 ± 6 23.2 ± 12 0.006 0.03 0.01
9:30 a.m.
1001-290 A New Concept of Stent: The Multilayer Stent. First 
Human Study in Peripheral Aneurysm
Michel Henry, Antonios Polydorou, Nourredine Frid, Patricia Gruffaz, Isabelle Henry, 
Michelle Hugel, Michel Henry, Nancy, France
Background: Peripheral aneurysms were traditionally treated surgically, but interventional 
procedures are more and more proposed using covered stents or endografts with a high 
technical success rate, but some problems are not solved like protection of aneurysm 
rupture, endoleaks, stent thrombosis. We developed a new concept of stent, the Multilayer 
stent (M.S) to treat aneurysms and try to avoid some drawbacks encountered with 
endografts.
Material and Methods: This M.S is a 3 Dimensional braided tube made of several 
interconnected layers without any covering. Our earliest tests,through studies as theorical 
simulation as computerized Fluid dynamics, Molecular Modelization and through in vitro and 
in vivo tests.demonstrate that this MS reduce the velocity in the aneurismal sac up to 90% by 
modifying the hemodynamic conditions.. A saccular aneurysm without collateral branch will 
thrombose quickly. If a collateral branch is present the ﬂow is directed towards this branch 
leading to shrinkage of the aneurysm. Animal experiments show excellent results.
Results: 7 peripheral aneurysms in 7 patients (male: 5), mean age: 65 +/-7 years were 
treated with the M.S.
Location: iliac (n5), popliteal (n 1), renal (n 1),
Approach way: ipsilateral femoral through 6/7 F sheath.
Immediate technical success: 7/7. At 6 month follow-up angiographic control showed 
complete cure of all aneurysms with excellent arterial patency.
Excellent long term follow up (Ctscan at 33 months) of the renal aneurysm will be 
presented.
Conclusion: A new concept of stent, the multilayer stent (without any covering) is 
developed to treat aneurysm. It opens a new approach to treat arterial diseases as 
aneurysms. The results obtain with the ﬁrst human cases seems promising. A larger 
study is ongoing.
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1001-293 The Efﬁcacy and Safety of Prasugrel With and Without 
a Glycoprotein IIb/IIIa inhibitor in Patients With Acute 
Coronary Syndromes Undergoing Percutaneous 
Intervention: A TRITON-TIMI 38 Analysis
Michelle L. O’Donoghue, Stephen D. Wiviott, Sabina A. Murphy, Carolyn H. McCabe, 
Elliott M. Antman, Eugene Braunwald, Brigham and Women’s Hospital, Boston, MA
Background: Prasugrel has been shown to signiﬁcantly reduce cardiovascular (CV) events 
as compared to clopidogrel in patients with ACS undergoing percutaneous intervention 
(PCI). Prasugrel has both rapid and potent effects on platelet inhibition. The efﬁcacy and 
safety of prasugrel in the setting of potent platelet inhibition with a glycoprotein IIb/IIIa 
inhibitor (GPI) remains unknown.
Methods: TRITON-TIMI 38 randomized 13,608 subjects with ACS undergoing PCI to 
prasugrel or clopidogrel, in addition to standard therapy. GPI use was at the physician’s 
discretion. To examine the acute effects of GPI, we evaluated endpoints at 30 days.
Results: 7413 subjects (54.5%) received a GPI during index hospitalization. There was 
a consistent beneﬁt of prasugrel over clopidogrel in reducing CV death, MI or stroke in 
patients who did (HR 0.76, 95% CI 0.64-0.90) and did not receive a GPI (HR 0.78, 95% 
CI 0.63-0.97, P interaction=0.83). Prasugrel signiﬁcantly reduced the risk of MI and stent 
thrombosis irrespective of whether or not patients were treated with a GPI. Although 
subjects treated with a GPI had a higher absolute rate of bleeding, the relative risk of TIMI 
major bleeding with prasugrel versus clopidogrel was not signiﬁcantly different in patients 
who were and were not treated with GPI (P int=0.39).
Conclusion: Prasugrel signiﬁcantly reduced CV death, MI or stroke after PCI regardless 
of whether a GPI was used. GPI use did not signiﬁcantly alter the risk of bleeding with 
prasugrel as compared to clopidogrel. 
9:30 a.m.
1001-294 Addition of Antialdosterone Treatment to Optimal 
Therapy Improves Cardiac Geometry And Function 
in Systolic Heart Failure Patients With The Metabolic 
Syndrome: The AREA-IN-CHF Study
Marcello Chinali, Giovanni de Simone, GianFrancesco Mureddu, Ilaria Botta, Giuseppe 
Cacciatore, Maurizio Porcu, Aldo P. Maggioni, Alessandro Boccanelli, Federico II 
University Hospital, Naples, Italy, S.Giovanni-Addolorata Hospital, Rome, Italy
Background: Metabolic Syndrome (MetS), negatively inﬂuences cardiac phenotype 
and outcome. Anti-aldosterone drugs have shown to reduce mortality in patients with 
heart failure (HF). There is no information on whether addition of anti-aldosterone therapy 
improves cardiac phenotype in HF patients with MetS, already on optimal pharmacological 
treatment.
Methods: The AREA-IN-CHF (AntiRemodeling Effect of Aldosterone receptors blockade 
with canrenone IN mild Chronic Heart Failure) is a prospective, randomized, double blind, 
placebo controlled study on anti-aldosterone treatment in patients with class 2 NYHA 
chronic HF and systolic dysfunction, on optimal treatment. At baseline, 467 patients (age 
62±10 yrs, 18% women) had available data for the assessment of MetS. Patients with 
ATPIII-deﬁned MetS (substituting waist girth with BMIq30 kg/m²) were included in the 
present analysis.
Results: At baseline, among 116 patients with MetS (25% of total study population; 62±9 
yrs, 20 women), no differences were found comparing the anti-aldosterone treatment-
group (N=58 or 50% of MetS patients) to the placebo-group in anthropometrics (age, 
gender, BMI, heart rate, blood pressure, medication class), metabolic proﬁle (creatinine, 
fasting glucose, HDL-C, triglycerides,B-type natriuretic peptide [BNP]), echocardiogarphic 
parameters (left ventricular [LV] mass index, left atrial diameter, relative wall thickness, 
LV ejection fraction, stroke volume, mitral E/A ratio, E deceleration time and IVRT; for all 
p=NS). After one year follow-up, the placebo group did not show any signiﬁcant variation 
in echocardiographic parameters. In contrast in the anti-aldosterone treatment-group, 
while no signiﬁcant variation in systolic blood pressure and heart rate were observed, 
signiﬁcant reduction was found in LV mass (-5.82±1.47g/m2.7), left atrial diameter 
(-0.28±0.09cm), BNP (-46.6±15.9pg/mL) paired with a signiﬁcant increase in LV ejection 
fraction (+3.05±1.04%; p for all<0.005).
Conclusion: In class 2 NYHA chronic HF patients with MetS, anti-aldosterone treatment 
signiﬁcantly reduces circulating BNP, LV mass and left atrial size and signiﬁcantly 
increases LV ejection fraction.
9:30 a.m.
1001-295 Dyslipidemia and Heart Failure Risk: The Framingham 
Heart Study
Raghava S. Velagaleti, Joseph Massaro, Ramachandran S. Vasan, Sander J. Robins, 
William B. Kannel, Daniel Levy, Framingham Heart Study, Framingham, MA, National 
Heart, Lung, and Blood Institute, Bethesda, MD
Background: The relations of lipid concentrations to heart failure risk have not been 
comprehensively elucidated.
Methods: In 6860 Framingham Heart Study participants (mean age 44 years; 54% 
women) free of baseline coronary heart disease, we related total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), and non-HDL-C to heart failure incidence during 
long-term follow-up, adjusting for clinical covariates and myocardial infarction at baseline 
and updating these at follow-up examinations.
Results: Over a mean follow-up of 26 years, 680 participants (49% women) developed 
heart failure. Unadjusted heart failure incidence was 8.2%, 7.9% and 6.1% in the low TC 
(<200 mg/dl), low non-HDL-C (<160 mg/dl) and high HDL-C (q55 [men], q65 [women] mg/
dl) groups respectively and 12.7%, 13.8% and 12.8% in the high TC (q240 mg/dl), high non-
HDL-C (q190 mg/dl) and low HDL-C (<40 [men], <50 [women] mg/dl) groups respectively. 
In multivariable models, baseline TC, non-HDL-C, and HDL-C, modeled as continuous 
measures, carried heart failure hazards (conﬁdence interval) of 1.10 (1.02-1.19), 1.19 
(1.11-1.27) and 0.82 (0.75-0.90) respectively per standard deviation increment. In models 
updating lipid concentrations periodically, the corresponding hazards (conﬁdence interval) 
were 1.17 (1.10-1.26), 1.23 (1.16-1.31) and 0.77 (0.70-0.85). Participants in the highest 
categories of baseline TC, non-HDL-C, and HDL-C experienced 20% and 29% higher 
and 40% lower heart failure risk respectively, compared to those in the lowest categories. 
Hazards associated with non-HDL-C and HDL-C remained statistically signiﬁcant after 
additional adjustment for interim myocardial infarction.
Conclusions: Dyslipidemia carries heart failure risk independent of its association with 
myocardial infarction suggesting that lipid modiﬁcation may be a means for reducing heart 
failure risk.
9:30 a.m.
1001-296 The B1 Adrenoceptor Ser49Gly Polymorphism Is 
Associated With LV Reverse Remodelling Changes 
in Response to B-Blockers in African American Heart 
Failure Subjects
Ronald Zolty, Mona Cantu, Benjamin Horne, Simon Shakar, JoAnn Lindenfeld, Brian 
Lowes, Michael Bristow, Albert Einstein College of Medicine, Bronx, NY, University of 
Colorado Health Sciences Center, Aurora, CO
Background: Long term stimulation of the sympathetic nervous system is associated with 
myocardial remodeling. Large randomized trials have demonstrated that B-blockers (BB) 
improve mortality and ejection fraction (EF) in heart failure (HF) patients. Improvement of 
the EF with BB therapy displays a high degree of inter-individual and inter-ethnic variation 
that might be explained by underlying genetic variation. The B1 adrenergic receptor (AR) 
play a critical role for maintenance of homeostasis in the human heart. The B1 389 and 49 
AR polymorphisms have been shown to act as disease modiﬁers in HF. Given the greater 
signal transduction capacity associated with Arg389, we hypothesized that patients with 
the Arg389 homozygous genotype of the B1 AR would demonstrate a greater reverse-
remodeling effect to BB therapy.
Methods: 485 patients with EF a 40% from any etiology were selected from the HF 
Clinic at the University of Colorado Hospital and correlation between the different B1
AR genotypes and LV dimension measurement response to BB therapy was evaluated 
retrospectively in Caucasian, African American and Hispanic HF patients.
Results: For the codon 389 polymorphism, there was no signiﬁcant statistical difference 
in the decrease of the left ventricular end diastolic dimension (LVEDD) among the three 
genotypes among any of the three ethnic groups. There was a trend showing that patients 
Arg389 homozygous patients had a greater decrease in their LVEDD compared to Gly389 
homozygous patients. None of the three B1 389 AR haplotypes was statistically linked to a 
decrease in the LVESD (left ventricular end systolic dimension) or fractional shortening (FS).
For the codon 49 polymorphism, the homozygous Gly49 AR African American non-
ischemic HF patients had a statistically signiﬁcant decrease in their LVEDD compared to 
African American Ser49 homozygotes (-0.95±0.84cm versus -0.22± 0.59cm, P=0.036). 
There was, however, no other signiﬁcant difference among the three 49 B1 AR genotypes 
regarding the decrease in the LVEDS or FS.
Conclusions: Signiﬁcant correlation between B1 49 AR genotype and LV remodeling 
in terms of LVEDD was found in African American HF patients with non-ischemic 
cardiomyopathy.
JACC March 10, 2009 ABSTRACTS - Best Poster Awards Competition   A461
B
est P
oster A
w
ards C
om
petition
3:30 p.m.
1001-297 Outcomes of Hypertrophic Cardiomyopathy Patients 
With Abnormal Papillary Muscle Morphology and 
Dynamic Left Ventricular Outﬂow Tract Obstruction 
Undergoing Surgical Papillary Muscle Reorientation
Deborah H. Kwon, Nicholas G. Smedira, Maran Thamilarasan, Bruce W. Lytle, Harry 
Lever, Milind Y. Desai, Cleveland Clinic Foundation, Cleveland, OH
Background: In hypertrophic cardiomyopathy (HCM), biﬁd hypermobile papillary 
muscles (PM) can lead to dynamic left ventricular outﬂow tract gradient (LVOTG), even 
without severe basal septal hypertrophy. Such patients might beneﬁt from surgical PM 
reorientation (PMR, ﬁxing the mobile PM to posterior LV structure to reduce mobility). We 
report characteristics and outcomes of HCM patients undergoing surgical PMR vs. those 
undergoing standard surgical procedures. 
Methods: Of 204 consecutive HCM patients (mean age 53 ± 14 years, 52 % men) 
who underwent surgery (excluding patients undergoing aortic valve replacement) 
for symptomatic dynamic LVOTG between 1/07 and 7/08, 22 had PMR. A consensus 
decision regarding type of surgery (including PMR) was made after detailed imaging 
assessment. Pre and post-operative maximal (resting or provocable) LVOTG were 
recorded on echocardiography. Symptoms, survival and freedom from reoperation during 
follow-up were recorded.
Results: The characteristics of the study group are shown in table. In group 4, 11 had 
PMR while 11 had PMR + mini-myectomy (< 5 mm). Mortality was 0 %. At 181 days 
(interquartile range 72-232 days), 21/22 patients were asymptomatic. One patient had 
symptomatic LVOTG of 87 mm Hg requiring mitral valve replacement.
Conclusions: In HCM patients with biﬁd hypermobile PM (+/- basal septal hypertrophy), 
PMR reproducibly reduces LVOTG while avoiding mitral valve replacement. Long-term 
outcomes need to be ascertained.
Group 1
Extensive 
Myectomy 
(n = 143 )
Group 2
Extensive 
Myectomy + 
Mitral valve 
repair
(n = 31 )
Group 3
Extensive 
Myectomy + 
Mitral valve 
replacement
(n = 8) 
Group 4
PM
Reorientation 
+/- mini-
myectomy 
(< 5 mm) 
(n= 22)
P value
Age (years) 
Male
54 ± 14
69 (48 %)
53 ± 12
18 (58 %)
57 ± 18
3( 38 %)
50 ± 14
16 (73 %)
0.5
0.1
Hypertension
Atrial ﬁbrillation
76 (53 %)
7 (5 %)
18 (58 %)
7 (23 %)
6 (75 %)
0 (0 %)
13 (59 %)
0 (0 %)
0.6
0.005
Syncope
Beta-blocker 
35(24 %)
118(83 %)
6 (19 %)
23 (74 %)
0 (0 %)
8 (100 %)
4 (18 %)
15 (68 %)
0.2
0.1
Pre-operative 
New York Heart 
Association Class 
q II 
197(95 %) 30 (97 %) 8 (100 %) 21 (95 %) 0.8
Septal thickness 
LV ejection 
fraction (%)
2.2 ± 0.5
63 ± 5
2.0 ± 0.4
61 ± 6
2.1 ± 0.4
64 ± 5
1.6 ± 0.3
61 ± 5
<0.001
0.3
Baseline maximal 
LVOTG (mm Hg) 103 ± 32 99 ± 31 117 ± 31 114 ± 36 0.2
Hospital length 
of stay
Intensive care 
length of stay
8 ± 5
1.6 ± 1.3
8 ± 7
1.6 ± 1.5
10 ± 6
1.5 ± 0.9
6 ± 3
1.6 ± 1
0.2
0.9
Post surgical 
maximal LVOTG 
(mm Hg)
15 ± 18 16 ± 14 6 ± 8 16 ± 21 0.5
Reoperation 
during follow-up 0 0 0 1
3:30 p.m.
1001-298 Effects of Early Beta-Blockade on Left Ventricular 
Remodeling, Function, and Mortality in Experimental 
Organic Mitral Regurgitation: Surprisingly Adverse 
Impact
Min Pu, Zhaohui Gao, Xiaoxue Fan, Xin Zeng, William R. Davidson, Jr., Ohio State 
University, Columbus, OH, Penn State University College of Medicine, Hershey, PA
Background: Beta-blockade reduces morbidity and mortality in heart failure associated 
with attenuation of left ventricular (LV) remodeling and improvement of LV function. 
However, the effects of early beta-blockade on LV remodeling, systolic function and 
mortality in organic mitral regurgitation (MR) is unknown. Methods: Moderate to severe 
organic MR was surgically induced in 87 rats, which were randomized into the control 
(n=44) and the beta-blockade (n=43) groups. Carvedilol was started at the two weeks 
of the induction of MR and was given for 23 weeks. Echocardiography was performed 
at baseline and 1, 6, 12 and 24 weeks after the induction of MR. LV remodeling was 
assessed using LV dimensions and LV mass. LV systolic function was evaluated by LV 
fractional shortening (LVFS). Results: There were no differences in heart rate, LV size, 
LV mass and LVFS between the control and the beta-blockade groups at baseline. At 24 
weeks heart rate was lower in the beta-blockade group than the control group. LV was 
more dilated and LV mass was signiﬁcantly higher in the beta-blockade group than the 
control group. LVFS was lower in the beta-blockade group than the control group. The 
mortality tended to be higher in the beta-blockade group (Table). Conclusion: Early beta-
blockade worsens LV remodeling and function and increases mortality in organic MR. 
The strikingly negative impact of beta blockade in organic MR compared to heart failure 
warrant further investigation. (* p<0.01 Beta-blockade group vs. control group) 
Baseline Control Baseline Beta-blockade
24 weeks
Control
24 weeks Beta-
blockade
Heart rate 370±36 365±37 351±31 307±25*
LVEDD (cm) 0.80±0.06 0.81±0.05 1.14±0.13 1.27±0.14*
LV mass (g) 0.71±0.12 0.71±0.09 1.44±0.37 1.73±0.36*
LVFS (%) 41±7 41±8 38±6 33±7*
Mortality 4.5% 11.6%
3:30 p.m.
1001-299 The Relationship of Bisphosphonate Use to the 
Prevalence of Aortic Valve Calciﬁcation in Women: The 
Multiethnic Study of Atherosclerosis
Sammy Elmariah, Kevin D. O’Brien, Matthew J. Budoff, Jens Vogel-Claussen, Joseph 
A.C. Delaney, Valentin Fuster, Richard A. Kronmal, Jonathan L. Halperin, Zena and 
Michael A Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New 
York, NY, Collaborative Health Studies Coordinating Center, University of Washington, 
Seattle, WA
Background: Degenerative aortic valve disease frequently involves valve calciﬁcation 
(AVC) and progressive stenosis. Nitrogen-containing bisphosphonates (NCBP) inhibit 
farnesyl pyrophosphate synthase, an enzyme distal to HMG-CoA reductase in the 
mevalonate pathway. Experimental data suggest that NCBP therapy may reduce AVC.
Methods: The relationship of baseline NCBP use to the prevalence of AVC as measured 
with cardiac computed tomography in 3,636 women within the Multi-Ethnic Study of 
Atherosclerosis (MESA) was determined using regression modeling. Because studies 
from this cohort have demonstrated age-related differences for some AVC risk factors, 
women were stratiﬁed into ages a65 and >65 years.
Results: NCBP users (n=213) were older (66 ± 8 vs 62 ± 10 years; p<0.0001) than non-
users (n=3,423). Those receiving a NCBP had higher HDL-cholesterol (61 ± 17 vs 57 ± 
15 mg/dl; p<0.0001) and lower LDL-cholesterol (113 ± 33 vs 118 ± 32 mg/dl; p<0.05) than 
non-users, which may be partially explained by greater use of lipid lowering medications 
in the NCBP group (21 vs 16% p=0.06). A signiﬁcant interaction was noted between age 
and NCBP use (p=0.015). Stratiﬁed by age, 100 patients a65 years and 113 patients 
>65 years received a NCBP, 18 and 15 of which had AVC scores > 0 Agatston units, 
respectively. After adjustment for age, body mass index, ethnicity, study site, education, 
income, health insurance status, antihypertensive and lipid-lowering therapy, diabetes, 
smoking, blood pressure and cholesterol levels, NCBP use was associated with a greater 
risk of AVC in women a65 years old (n=2,138; RR=3.8 [95% CI 2.3, 6.4], p<0.0001), but 
not in women >65 years old (n=1,498; RR=0.7 [95% CI 0.4, 1.1], p=0.11).
Conclusion: In the diverse MESA cohort, NCBP use was unexpectedly associated with 
increased risk for AVC in younger, but not older, women. It is unclear whether this ﬁnding 
may be due to age-related differences in AVC pathogenesis, drug effect, or indication 
bias. Given the potential clinical implications of these ﬁndings for women prone to AVC, 
this study warrants replication in other cohorts to rule out a chance ﬁnding and to further 
evaluate the effects of NCBP on valve calciﬁcation and function.
3:30 p.m.
1001-300 Elimination of Gender and Racial Differences in 
Recognition and Treatment of Patients at Risk for 
Sudden Cardiac Death
William C. Daniel, Brian Ramza, John Spertus, Cardiovascular Consultants, Kansas 
City, MO, MO
Background: Although Sudden Cardiac Death (SCD) is a leading cause of death, it can 
be prevented by the appropriate use of intracardiac deﬁbrillators (ICDs). Recent reports 
document gender and racial differences in the recognition and treatment of patients at 
risk for SCD.
Methods: An electronic decision support program was implemented at 1 site. The 
recognition for ICD eligibility and subsequent treatment among all patients examined at 
the intervention site were compared with patients seen during the same period at usual 
care (control) sites. We focused this analysis on differences in recognition and treatment 
for racial minorities and women.
Independent data collection and review for every patient visiting the Active and Control 
groups over a 2-month period was conducted.
Results: At the intevervention site, 125 patients were examined, while 126 patients were 
seen at the usual care site during this same period. At the intervention site, 93% of ICD-
eligible patients were recognized as compared with 70% at the control site. Importantly, 
no signiﬁcant differences in the rates of recognition among women was observed at the 
intervention site (92% in men vs. 95% in women; p<0.0001), but were present in the 
control site (80% vs. 50%; p<0.0001). Similar trends were observed for minorities and the 
ultimate implantation of ICDs.
Conclusions: This single-center study suggests that real-time decision support may help 
eliminate racial and gender differences in the recogntion and treatment of patients at 
risk for SCD.
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Results
Recognition ICDImplantation
Intervention 
(%) Control (%) p value
Intervention 
(%) Control (%) p value
Total 117/126(93%)
88/125
(70%) <0.0001
40/126
(32%)
14/125
(11%) <0.0001
Men 82/89 (92%) 66/83(80%) <0.0001 32/89 (36%)
12/83
(14%) <0.0001
Women 35/37 (95%) 21/42(50%) <0.0001 12/37 (33%) 2/42 (5%) <0.0001
Caucasion 94/102(92%)
78/110
(71%) <0.0001
32/102
(31%)
14/110
(13%) <0.0001
Non
Caucasion 23/24 (96%) 6/9 (67%) <0.0001 8/24 (33%) 0/9 (0%) <0.0001
3:30 p.m.
1001-301 Long-Term Trends in Mortality, Readmission and Length 
of Stay After Hospitalization for Heart Failure Among 
Medicare Patients
Jersey Chen, Yun Wang, Joseph S. Ross, Héctor Bueno, Jeptha P. Curtis, Elizabeth 
E. Drye, Patricia S. Keenan, Judith H. Lichtman, Sharon-Lise T. Normand, Geoffrey 
C. Schreiner, John A. Spertus, Maite Vidán, Yongfei Wang, Zhenqui Lin, Harlan M. 
Krumholz, Yale University School of Medicine, New Haven, CT
Background: Long-term national trends on mortality, readmission and length of stay for 
elderly patients after admission for heart failure (HF) are unknown.
Methods: Patients age 65 yrs or greater hospitalized for HF from 1992-2006 were 
identiﬁed from Medicare administrative claims. Hospital-level 30d mortality rates from 
admission, 30d all-cause readmission rates from discharge, and length of stay (LOS) 
were calculated for each year. For patients with more than 1 HF hospitalization to the 
same hospital in a given year, one admission was randomly selected.
Results: For the 9,870,434 Medicare HF hospitalizations from 1992-2006, 30d mortality 
declined from 11.8% to 10.1%, while LOS decreased from 7.9 to 5.3 days. However, 
30d all-cause readmission rates after HF admission increased substantially by 4.7%. The 
proportion of patients discharged home decreased by an absolute 14.5% while discharge 
to intermediate care facilities/skilled nursing facilities increased by 7.8%. Inpatient deaths 
fell by an absolute 4.1%.
Conclusions: Over the past 15 years, inpatient mortality and LOS have declined 
substantially while 30d mortality has declined by a small amount and 30-day readmission 
has increased. The increase in HF readmission rate demonstrates the importance of 
identifying ways improve performance on this important outcome. 
Year LOS 30-day outcomes (%) Discharge status (%)
Readmission Mortality Home ICF/SNF Dead Transfer out to acute 
care hospital 
1992 7.9 18.4 11.8 62.6 11.8 8 2.7
1994 7.1 19.0 11.3 60.3 13.0 7.1 2.8
1996 6.2 20.0 11.1 57.7 15.0 6.1 3.1
1998 5.8 20.7 10.2 58.1 16.5 5.1 3.3
2000 5.7 21.4 10.8 56.6 16.9 5.4 3.4
2002 5.7 22.3 10.7 54.9 17.0 5.2 3.5
2004 5.4 22.9 10.2 49.3 18.4 4.5 3.2
2006 5.3 23.1 10.1 48.1 19.6 3.9 2.9
3:30 p.m.
1001-302 Do Changes in Atherosclerotic Plaque Volume by 
Intravascular Ultrasound Predict Clinical Outcomes? A 
Meta-Regression Analysis
Vineet K. Dandekar, Javier Valle, Zachary D. Goldberger, Paul S. Chan, Brahmajee K. 
Nallamothu, University of Michigan, Ann Arbor, MI
Background: Direct quantiﬁcation of atherosclerotic plaque volume, as measured 
by intravascular ultrasound (IVUS), has been proposed as a surrogate endpoint for 
evaluating novel drugs. We hypothesized that improvements in plaque volume by IVUS in 
randomized clinical trials would be associated with fewer clinical outcomes.
Methods: We performed a literature search to identify English-language RCTs from 1990 
to 2008 that used IVUS to quantify progression of plaque volume over time. Eligible studies 
reported (1) either normalized total atheroma volume (TAV) or percent atheroma volume 
(PAV) q 6 mos apart and (2) death or MI. Random-effects meta-regression assessed if 
changes in plaque volume correlated with a lower odds ratio (OR) for outcomes.
Results: 11 studies were identiﬁed with 3728 patients and mean follow-up of 18 mos. 
RCTs evaluated both statin and non-statin therapies (succinobucol, rimonabant, ACAT 
inhibitors, torcetrapib, pioglitazone, ACE inhibitors, and amlodipine). Mean age was 
59, 25% were women, and 28% were diabetics. During meta-regression, we found no 
evidence that changes in plaque volume by IVUS correlated with a lower OR of death or 
MI in 10 RCTs reporting TAV (p=0.87) (Figure). Results were similar when our analysis 
was restricted to RCTs reporting PAV or with q 1-yr follow-up.
Conclusions: We found no correlation between improvements in plaque volume by IVUS 
and a lower OR of death or MI in RCTs, urging for more cautious use of this surrogate 
endpoint in evaluating novel drugs. 
3:30 p.m.
1001-303 The Incidence and Risk of High-Grade Hypertension 
in Cancer Patients Treated With Bevacizumab: A Meta-
Analysis of Randomized Controlled Studies
Bhargava C. Pulipati, David Chu, Shenghong Wu, SUNY Stony Brook University Medical 
Center, Stony Brook, NY
Background: Hypertension is one of the common side effects of bevacizumab, a 
humanized monoclonal antibody that inhibits the biologic activity of vascular endothelial 
growth factor (VEGF), and is used widely for cancer therapy. Currently the risk of severe 
hypertension associated with bevacizumab is unclear. We performed a systematic review 
and meta-analysis of published clinical trials to examine the incidence and risk of high-
grade hypertension.
Methods: Databases from PUBMED and the Web Science from January 1966 until 
July 2008 and abstracts presented at the American Society of Clinical Oncology 
(ASCO) conferences from January 2000 to July 2008 were searched to identify relevant 
studies. Eligible studies included prospective randomized controlled clinical trials in 
which standard antineoplastic therapy was administered with and without the use of 
bevacizumab. Summary incidence, relative risk (RR), and 95% conﬁdence interval (CI) 
were calculated employing a ﬁxed or random-effects model based upon the heterogeneity 
of the included studies.
Results: Twenty randomized controlled studies including 13,104 patients with a variety 
of tumors were identiﬁed for analysis. The incidence of all-grade hypertension in patients 
receiving bevacizumab was 23.6% (95% CI: 20.5-27.1%) with 7.9% (95% CI: 6.1-10.2%) 
being high-grade (grade 3 or 4). Patients treated with bevacizumab had an increased risk 
of developing high-grade hypertension with a RR of 5.1 (95% CI: 4.1-6.5, p<0.001) in 
comparison with controls. The increased risk of high-grade hypertension was observed in 
patients receiving bevacizumab at 2.5 mg/kg/week (RR= 5.0, 95% CI: 3.8-6.7, p<0.001) 
as well as 5 mg/kg/week (RR= 4.9, 95% CI: 3.4-6.9, p<0.001). Bevacizumab may increase 
the risk of high-grade hypertension more evidently in patients with renal cell carcinoma 
(RR=9.0, 95% CI: 2.7-29.7) than non-RCC malignancies (RR=5.0, 95%CI: 4.0-6.4).
Conclusion: There is a signiﬁcantly increased risk of high-grade hypertension in cancer 
patients treated with low and high doses of bevacizumab. The risk may vary with tumor 
type. Close monitoring and adequate management is highly recommended to decrease 
cardiovascular complications.
3:30 p.m.
1001-304 Accurate Estimation of Central Systolic Blood Pressure 
Using an Oscillometric Blood Pressure Monitor
Hao-min Cheng, Kang-Lin Wang, Ying-Hwa Chen, Shing-Jong Lin, Lung-Ching Chen, 
Shih-Hsien Sung, Wen-Shin Lee, Philip Yu-An Ding, Wen-Chung Yu, Jaw-Wen Chen, 
Chen-Huan Chen, National Yang-Ming University, Taipei, Taiwan, Taipei, Taiwan,ROC, 
Taipei Veterans General Hospital, Taipei, Taiwan,ROC
We developed and validated a novel method to estimate the central aortic systolic 
pressure using an oscillometric blood pressure monitor
Background:Current noninvasive techniques for assessing central aortic pressure need 
the recording of an arterial pressure wave using an expensive high-ﬁdelity applanation 
tonometer.
Methods:Invasive high-ﬁdelity right brachial and central aortic pressure waveforms, and 
left-brachial pulse volume recording, representing the noninvasive brachial pressure wave, 
were obtained at baseline and 3 minutes after administration of sublingual nitroglycerin in 
100 patients during cardiac catheterization.
Results:In the initial 50 patients, invasive central aortic systolic pressure was accurately 
predicted by a multi-variate regression equation generated from the comprehensive 
analysis of the invasive brachial pressure wave for parameters related to wave reﬂection 
and arterial compliance (r=0.98, P<0.001, mean difference=0.1±4.3 mmHg). A second 
regression equation was similarly constructed from the noninvasive brachial pressure 
wave. The central systolic pressure was also accurately predicted by the second regression 
equation using the noninvasive brachial pressure wave calibrated by oscillometric cuff 
systolic and diastolic pressures (r=0.92, P<0.001, mean difference=-3.3±8.0 mmHg). 
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The two regression equations were validated in subsequent 50 patients with very similar 
results: r=0.98 (P<0.001) and mean difference= 0.5±4.5 mmHg for the invasive model, 
and r=0.92 (P<0.001) and mean difference=-4.7±8.0 mmHg for the noninvasive model.
Conclusions:Central aortic systolic pressure can be estimated accurately by 
analysis of the noninvasive brachial pressure wave from an oscillometric blood 
pressure monitor. This innovation may further expand the role of oscillometric 
blood pressure monitor in the management of hypertension.
3:30 p.m.
1001-305 Activation of Endothelin-1 Pathway During Methionine-
Induced Homocysteinemia, Mediates Endothelial 
Dysfunction in Hypertensive Individuals
George Bouras, Dimitris Tousoulis, Charalambos Antoniades, Antigoni Miliou, Kyriakoula 
Marinou, Alexios Antonopoulos, Nikos Papageorgiou, Costas Tentolouris, Charalambos 
Vlachopoulos, Elli Stefanadi, Costas Tsiouﬁs, Christodoulos Stefanadis, 1st Cardiology 
Department, Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Endothelin-1 (ET-1) is a key regulator of arterial blood pressure in humans, 
and homocysteinemia is associated with increased oxidative stress. We examined the 
impact of acute homocysteinemia on endothelial function in hypertensive and healthy 
individuals, and the potential role of ET-1.
Methods: Thirty-ﬁve hypertensive subjects and 30 healthy volunteers received methionine 
(100mg met/Kg BW) after intake of vitamins C (2g) plus E (800IU) (16 hypertensives 
(HTN+vit) and 15 healthy (C+vit)) or placebo (18 hypertensives (HTN+placebo) and 15 
healthy (C+placebo)). Endothelium dependent dilatation (EDD) was evaluated by gauge-
strain plethysmography, at baseline and 4 hrs post loading (4hPML). ET-1 and lipid 
hydroperoxides (per-ox) levels were measured by ELISA.
Results: Homocysteine was similarly increased in hypertensives (by 22.2±1.26μM 
p<0.0001) and healthy (by 23.2±2.22 μM, p<0.0001), and remained unaffected by 
pre-treatment with antioxidants. EDD was decreased in HTN+placebo (75.4±11.5 
to 51.6±7.3%, p<0.05) and C+placebo (96.7±9.6 to 52.2±6.5%, p<0.0001), while 
antioxidants did not prevent this effect in either HTN+vit (76.4±8.8 to 53.7±7.8%, p<0.01) 
or C+vit (86.6±10.5 to 41.1±6.3%, p<0.001). Importantly, ET-1 was increased 4hPML 
only in hypertensives (HTN+placebo: 1.09±0.3 to 1.40±0.4pg/ml, p<0.05) an effect not 
prevented by antioxidants (HTN+vit: 0.82±0.08 to 1.1±0.09pg/ml p<0.01). Per-ox were 
signiﬁcantly decreased in the HTN+vit (195±32 to 130±30pg/ml, p<0.05) but not in HTN-
placebo (239±36 to 236±33 pg/ml, p=NS). Per-ox remained unchanged in C+Vit (221±31 
to 200±38pg/ml p=NS) and increased in C+placebo (216±33 to 314±43pg/ml, p<0.05). 
No effect of methionine-loading was observed on ET-1 levels in healthy (C+placebo: 
1.96±0.84 to 1.87±0.77pg/ml and C+vit: 3.59±1.35 to 2.84±1.15pg/ml, p=NS).
Conclusions: Experimental homocysteinemia rapidly blunts endothelial function in both 
hypertensive subjects and healthy individuals. The rapid elevation of ET-1 levels, observed 
only in hypertensives, suggests that ET-1 may be the key mediator of homocysteine-
induced endothelial dysfunction, independently of oxidative stress.
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1002-306 Coexpression With Trafﬁcking-Competent KvLQT1 
Selectively Rescues HERG LQT2 Mutations
Kenshi Hayashi, Hidekazu Ino, Noboru Fujino, Katsuharu Uchiyama, Eiichi Masuta, 
Akira Funada, Yuichiro Sakamoto, Toshinari Tsubokawa, Akihiko Muramoto, Jeffrey 
R. Balser, Sabina Kupershmidt, Haruhiro Higashida, Masakazu Yamagishi, Kanazawa 
University, Kanazawa, Japan, Vanderbilt University, Nashville, TN
Background: Mutations in the HERG and KvLQT1 genes cause the Long QT Syndrome such 
as LQT1 and LQT2. The majority of HERG mutations result in faulty intracellular trafﬁcking. 
It has been reported that KvLQT1 co-expression with HERG in cultured cells resulted in an 
increase in IHERG density. Under these conditions, HERG and KvLQT1 were found to interact 
biochemically and to co-localize in myocytes. Therefore, we speculate that KvLQT1 facilitates 
HERG expression because of a codependency during biogenesis/trafﬁcking. However, few 
data exist regarding impact of co-expression of KvLQT1 on HERG functions.
Methods: CHO-K1 cells were transfected with HERG cDNA and/or KvLQT1 cDNA. Whole-
cell potassium currents were recorded using patch-clamp techniques in the absence and 
presence of the HERG blocker dofetilide. IHERG currents were obtained by subtracting the 
dofetilide insensitive component (IKvLQT1) from the composite current (IHERG+IKvLQT1).
Results: Although the tail current density of HERG was approximately doubled by 
KvLQT1 co-expression, it was not altered in the presence of the trafﬁcking defective LQT1 
mutation T587M. The LQT2 mutation HERGM124T (19.0 ± 5.2 pA/pF , n=8) was rescued to 
wild type levels by KvLQT1 co-expression (45.6 ± 8.1 pA/pF , n=9, p<0.05 vs HERGM124T),
but not by KvLQT1T587M (20.2 ± 4.5 pA/pF , n=8). The tail current density of the trafﬁcking 
defective LQT2 mutations, HERGG601S (14.8 ± 2.2 pA/pF, n=12) and HERGF805C (1.8 ± 0.3 
pA/pF, n=15) were also signiﬁcantly increased by KvLQT1 co-expression (G601S, 28.1 
± 2.8 pA/pF, n=12; F805C, 4.3 ± 0.7 pA/pF n=15, p<0.05 vs HERGG601S or HERGF805C). 
In contrast, a nonfunctional, but trafﬁcking competent LQT2 mutation HERGG628S and the 
non-glycosylatable HERGN598Q were not increased.
Conclusions: These results demonstrate that KvLQT1 increases HERG current density 
by enhancing HERG protein trafﬁcking and increasing surface membrane expression 
of HERG channels. The clinical phenotype of the patients with trafﬁcking defective LQT 
mutations can be milder in LQT2 than in LQT1.
9:30 a.m.
1002-307 Atrial Remodeling Occurs Early With the Development 
of Hypertension in the Ovine Atria
Dennis H. Lau, Lorraine Mackenzie, Darren J. Kelly, Pawel Kuklik, Prashanthan Sanders, 
Cardiovascular Research Centre, Department of Cardiology, Royal Adelaide Hospital, 
Adelaide, Australia, Department of Medicine, St. Vincent’s Hospital, University of 
Melbourne, Melbourne, Australia
Background: Hypertension is strongly associated with atrial ﬁbrillation (AF) but the 
effects of short-term hypertension on atrial remodeling are unknown.
Methods: Sixteen Merino Cross sheep (54±11kg) were studied. Ten had induced 
hypertension for 7±4 weeks via the “one-kidney, one-clip” model while six were controls. 
MRI was used to assess functional changes and open-chest electrophysiological study 
performed using custom made 128-electrode epicardial plaque applied to both right (RA) 
and left atria (LA). Effective refractory periods (ERP) and conduction velocity (CV) were 
assessed at four pacing cycle lengths across ten sites. Tissue specimens were harvested 
for structural analysis.
Results: The hypertensive group demonstrated the following compared to controls: higher 
BP (176/119 vs. 95/62mmHg; P<0.0001); enlarged LA (42 vs. 29mL; P<0.05); reduced LA 
ejection fraction (25 vs. 31%; P<0.05); preserved left ventricular ejection fraction (41.9 vs. 
44.3%; P=NS); higher mean ERP (RA: 172±23 vs. 157±10ms, P<0.001; LA: 143±14 vs. 
127±5ms, P<0.001); slower mean CV (RA: 0.76±0.02 vs. 0.99±0.10m/sec, LA: 0.81±0.05 
vs. 1.00±0.04m/sec, both P<0.0001); increased absolute range of conduction phase 
delay (P5-95: 11.9±1.2 vs. 9.9±0.5ms/mm; P=0.0009); higher conduction heterogeneity 
index (P5-95/P50: 1.8±0.07 vs. 1.4±0.02; P<0.0001); greater AF inducibility (24 vs. 3%; 
P=0.03) and increased AF durations (281±624 vs. 11±13sec; P=0.04). Picrosirius red 
staining of atrial tissues revealed increased interstitial ﬁbrosis (p<0.05) with evidence of 
inﬂammatory cell inﬁltrates.
Conclusions: Short-term hypertension is associated with signiﬁcant atrial remodeling 
characterized by atrial enlargement, inﬂammatory cell inﬁltrates, interstitial ﬁbrosis, 
slowed/heterogeneous conduction, increased ERP and greater propensity for AF. Early 
aggressive therapy for hypertension may prevent the development of arrhythmogenic 
atrial substrates.
9:30 a.m.
1002-308 Anticoagulant and Antiplatelet Therapy Use in Patients 
With Atrial Fibrillation and Coronary Artery Disease: 
Implications for the Risk of Mortality
Laurent Fauchier, Axel de Labriolle, Laurent Gorin, Emilie Nonin, Bruno Rauzy, Bertrand 
Pierre, Noura Zannad, Caroline Grimard, Jonathan Banayan, Dominique Babuty, 
Bernard Charbonnier, Centre Hospitalier Universitaire Trousseau, Tours, France
Background: There is few evidence on the optimal antithrombotic therapy for patients with 
atrial ﬁbrillation (AF) and coronary artery disease (CAD). The importance of antiplatelet 
therapy for prevention of recurrent myocardial ischemia is enhanced in patients undergoing 
percutaneous coronary intervention (PCI), but no studies speciﬁcally addressed this issue 
in patients who may also require anticoagulation because of AF.
Methods: All patients with AF and CAD seen in our institution between 2000 and 2007 
were identiﬁed and followed until December 2007. The patients were identiﬁed by a search 
in the hospital discharge records which include information on type of AF, co-existing 
conditions, performed procedures, medication at discharge and in-hospital death.
Results: Among 1799 patients with AF and CAD (age 75±10 years; 1415 men [79%]), 
432 underwent PCI and 299 had stent implantation. Coumarins were used in 968 patients 
(54%) and antiplatelet agents in 1151 patients (64%). Aspirin plus clopidogrel were used 
in 445 patients (25%), whereas 234 patients (13%) were discharged with triple therapy 
(coumarins, aspirin, and clopidogrel). During a follow-up of 607±757 days, 257 deaths 
were recorded. After adjustment for age, CHADS score, use of other medications, and 
other potential confounders, non-anticoagulation with coumarins increased mortality 
(hazard ratio [HR] = 2.40; 95%CI 1.84-3.14; p<0.0001) as did the lack of use of 
antiplatelet therapy (HR=1.81; 95%CI 1.38-2.36; p<0.0001). In a Cox-regression analysis, 
the factors independently associated with increased mortality were non-anticoagulation 
(p<0.001), lack of use of antiplatelet therapy (p<0.0001), renal failure (p<0.0001), heart 
failure (p=0.0005), CHADS2 score (p=0.0005) and older age (p=0.002). The results were 
similar when one considered separately patients with and without PCI: HR=3.11 and 
2.29 respectively for non-anticoagulation, and HR=2.32 and 1.73 for the lack of use of 
antiplatelet therapy.
Conclusions: Use of anticoagulation and antiplatelet therapy are both independently 
associated with a lower risk of death in patients with AF and CAD, whether one considers 
patients who underwent PCI or those who did not.
9:30 a.m.
1002-309 Mini-Epidemics of Hypoplastic Left Heart Syndrome?
Pirooz Eghtesady, Mathew Hall, Children’s Hospital, Cincinnati, OH
Background: Left-sided congenital heart diseases (LSCHD), including hypoplastic left 
heart syndrome (HLHS) are a signiﬁcant cause of neonatal morbidity and mortality. 
Their etiology remains unknown though some have suggested a hereditary component. 
Anecdotal reports of cluster presentation of affected infants suggest alternative etiologies. 
We tested the hypothesis that LSCHD can present as “mini-epidemics”, with a seasonal 
distribution.
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Methods: We conducted a retrospective analysis of the occurrence of LSCHD among a 
representative population of newborns from the United States, using data derived from 
the Pediatric Hospital Information Systems database (1996-2005; 38 children’s hospitals). 
Incidence rates were calculated using census-derived birth rates. Population and index 
case patterns were analyzed and the existence of seasonality for each of the diagnostic 
categories was determined by using Fisher’s Kappa test and Bartlett’s Kolmogorov-
Smirnov tests, and the strength of seasonality quantiﬁed by the autoregression R-squared 
(signiﬁcance at p<0.05). Spectral analyses of the rate of occurrence of LSCHD were 
performed to detect patterns of periodicity.
Results: A seasonal occurrence was found in infants with HLHS but not the other LSCHD in 
a time-series analysis over a 10-year period using three separate statistical tests, including 
a time-series analysis. Signiﬁcant seasonal differences occurred each year, with peaks in 
April and troughs in January. We found a signiﬁcant seasonal occurrence for HLHS but not 
for interrupted aortic arch, a heart defect with known strong genetic etiology.
Conclusions: There is a signiﬁcant seasonal pattern in presentation of HLHS, with 
preponderance in summer months. This is in contrast to the random pattern of other 
LSCHD. Environmental factor(s) may contribute to the pathogenesis of HLHS as in other 
diseases with strong seasonal patterns.
9:30 a.m.
1002-310 Laboratory Measures of Exercise Capacity and 
Ventricular Characteristics and Function Are Weak 
Correlates of Functional Health Status After Fontan: A 
Pediatric Heart Network Study
Brian W. McCrindle, Victor Zak, Lynn A. Sleeper, Stephen M. Paridon, Steven Colan, Tal 
Geva, Lynn Mahony, Page Anderson, Roger E. Breitbart, Renee Margossian, Richard V. 
Williams, Welton Gersony, Andrew M. Atz, The Hospital for Sick Children, University of 
Toronto, Toronto, ON, Canada
Background. Patients (pts) after Fontan are at risk for suboptimal functional health status. 
Associations with laboratory measures of exercise capacity and ventricular characteristics 
and function are not well understood, and are important for planning interventions and 
outcome measures for clinical trials.
Methods and Results. Parents completed the generic Child Health Questionnaire (CHQ) 
for 511 Fontan Cross-Sectional Study pts aged 6-18 years (61% male). Regression 
analyses were used to determine associations for CHQ Physical (45+12) and Psychosocial 
(47+11) Functioning Summary Scores (FSS) with standardized measurements from 
prospective exercise testing, echocardiography, magnetic resonance imaging (MRI), and 
brain natriuretic peptide (BNP). Interactions between laboratory measures and gender, 
dominant ventricular morphology (49% LV), staging with a cavopulmonary anastomosis 
(74%), age at Fontan, Fontan connection type and age at enrollment were also examined. 
Final multivariable regression model with exercise variables (maximal effort only pts) 
showed higher Physical FSS was only associated with higher maximum work rate, 
accounting for 9% of variation in Physical FSS. For echo, lower Tei index (particularly for 
pts with extracardiac lateral tunnel connections), lower BSA-indexed end-systolic volume, 
and the absence of AV valve regurgitation for pts having Fontan at age <2 years were 
associated with higher Physical FSS, accounting for 15% of variation in Physical FSS. For 
MRI, lower mass to end-diastolic volume ratio, and mid-quartiles of BSA-indexed end-
systolic volume (non-linear) were associated with higher Physical FSS, accounting for 
12% of variation. Lower BNP was signiﬁcantly but weakly associated with higher Physical 
FSS (1% of variation). Signiﬁcant associations for Psychosocial FSS with laboratory 
measures were fewer and weaker than with Physical FSS.
Conclusions. In relatively healthy Fontan pts, variation in exercise capacity and 
ventricular characteristics and performance explains only a small proportion of the 
variation in functional health status and, therefore, these measures may not be valid 
endpoints in trials of therapeutic interventions.
9:30 a.m.
1002-311 Noninvasive Quantiﬁcation of Systemic To Pulmonary 
Collateral Flow: A Major Source of Inefﬁciency in 
Patients With Superior Cavopulmonary Connections
Kevin K. Whitehead, Matthew J. Gillespie, Matthew A. Harris, Mark A. Fogel, Jonathan J. 
Rome, Children’s Hospital of Philadelphia, Philadelphia, PA
Background: Systemic to pulmonary collateral ﬂow (SPCF) is common in single 
ventricle patients (pts) with superior cavopulmonary connections (BDG). However, 
because there is no validated method to quantify SPCF, its clinical impact cannot be 
accurately evaluated. We hypothesize that the difference in aortic ﬂow (Ao) and caval ﬂow 
(SVC+IVC) will estimate SPCF. In addition the difference between measured pulmonary 
vein and pulmonary artery ﬂow (PV - PA) should provide a second independent estimator 
of SPCF, allowing for internal validation.
Methods: We measured the Ao, SVC, IVC, right PA (RPA), left PA (LPA), total left PV 
(LPV), and total right PV ﬂow (RPV) in 15 BDG pts during cardiac magnetic resonance 
imaging studies using through plane phase contrast velocity mapping. Two independent 
measures of SPCF were obtained: (1) Ao - (SVC + IVC). (2) (LPV-LPA) + (RPV-RPA). 
Values were normalized to BSA, Ao, and PV and comparisons made using paired student 
t-testing and linear correlation.
Results: SPCF ranged from 0.2-1.4 L/min for (1) and 0.2-1.6 L/min for (2) for an indexed 
SPCF of 0.5-2.8 L/min/m2 : 11-54% (mean 36%)of Ao and 19-77% (mean 54%) of PV. 
There was a strong linear correlation between the two methods (see ﬁg.).
Conclusions: We present a new noninvasive measurement of SPCF in BDG pts. 
Collateral ﬂow is a signiﬁcant hemodynamic burden in many pts with BDG. Future 
investigations will allow objective study of the impact of SPCF on outcome. This should 
prove an important clinical tool in managing these pts. 
9:30 a.m.
1002-312 Speckle Tracking Based Evaluation of Three-
Dimensional Strain: Validation Against Sonomicrometry
Muhammad Ashraf, Weihui Shentu, Zhiwen Zhou, David J. Sahn, Oregon Health & 
Science University, Portland, OR
Background: For evaluating cardiac mechanics, we tested a newly developed 3D speckle 
tracking based method for its ability to deﬁne a modeled infarct zone.
Methods: We studied ﬁve freshly harvested pig hearts. Each heart was mounted on a 
plastic ring in a water bath. A pulsatile pump was attached to LV cavity through a latex 
balloon with a known volume of water. Three 2 mm sonomicrometry (sono) crystals were 
placed on the LV anterior wall, forming a triangle with 1 and 2 along circumference and 
1 and 3 along long axis. Pulsatile ﬂow was generated by pushing 5 different calibrated 
stoke volumes (20-60ml) into the LV cavity at a constant rate of 60 beats/min. Full volume 
gated 4D images were acquired with a 3.5 MHz full matrix transducer on a Toshiba Artida 
ultrasound system at the rate >25 volume/sec. After obtaining baseline data at each stroke 
volume 2ml of gluteraldehyde was injected in the triangular area between sono crystals 
to simulate myocardial infarction. The study was repeated to acquire 3D and sono data at 
each stroke volume. Images were analyzed with online 3D WMT software and sono data 
analyzed in Sonosoft for computation of longitudinal and circumferential strain.
Results: With increases in stroke volume a corresponding increase in sono-derived strain 
(r2 = 0.87) and echo derived strain (r2 = 0.76) both longitudinal and circumferential, was 
seen. Sono and 4D also showed the decrease in both strain components (r2 = 0.85, 
P<0.05) in the infarct zone.
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1002-313 Coronary Computed Tomographic Angiography 
Effectively Directs Healthcare Resource Utilization
Kavitha M. Chinnaiyan, Aiden Abidov, Michael J. Gallagher, James Stewart, Gilbert L. 
Raff, William Beaumont Hospital, Royal Oak, MI, William Beaumont Hospital, Troy, MI
Background: Coronary computed tomography angiography (CCTA) has high diagnostic 
accuracy when compared to invasive coronary angiography (CATH) for the diagnosis of 
coronary artery disease (CAD) but there are limited data on its clinical effectiveness.
Methods: All patients undergoing CCTA imaging at William Beaumont Hospitals Royal 
Oak and Troy, MI are enrolled in a prospective quality assurance registry, including 
demographics, coronary risk factors, test ﬁndings and 3 month follow-up for cardiac 
events and testing.
Results: Between July 1, 2007 and Oct. 3, 2008 2,671 patients completed CCTA, data 
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collection and 3 month follow-up. Among these, 2,089 (78.2%) patients had no reported 
CAD, whereas 582 (21.8%) cases reported prior CAD (see Table). In patients without 
prior CAD, EC visits were similar, but hospitalizations were markedly reduced if CCTA 
showed no obstructive lesions (7.0% vs. 38.6%) as were noninvasive tests (3.9% vs. 
11.9%). CATH were similarly reduced (2.4% vs. 48.0%), as were coronary interventions 
(0.6% vs 19.8%) and coronary bypasses (0.2% vs. 6.7%); p values all < 0.001. Resource 
utilization in patients with prior CAD but no CCTA stenosis > 50% was similarly reduced 
with exception of stress tests.
Conclusions: CCTA reduces use of hospitalization, noninvasive and invasive procedures 
in low-risk patients.
Healthcare Resource Utilization 3 Mo After CCTA
Patients No Known CAD 
N=2089
CT Sten <=50% N=1760 
(84.3%)
CT Sten >50% N=327 
(15.7%)
P
Value
Hospital stays 123 (7.0%) 127 (38.6%) <0.001
Stress tests 68 (3.9%) 39 (11.9%) <0.001
Caths 42 (2.4%) 158 (48.0%) <0.001
PCIs 10 (0.6%) 65 (19.8%) <0.001
CABGs 4 (0.2%) 22 (6.7%) <0.001
Patients with Hx CAD 
N=582
CT Sten <=50% N=308 
(52.9%)
CT Sten >50% N=274 
47.1%
Caths 27 (8.8%) 78 (28.5%) <0.001
PCIs 8 (2.6%) 38 (13.9%) <0.001
CABGs 11 (3.6%) 50 (18.2%) <0.001
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1002-314 Cardiorespiratory Fitness Is Related to the Risk of 
Sudden Cardiac Death in Middle-Aged Men
Jari A. Laukkanen, Timo Makikallio, Rainer Rauramaa, Sudhir Kurl, Lapland Central 
Hospital, Rovaniemi, Finland, Research Institute of Public Health, University of Kuopio, 
Kuopio, Finland
Background: Few data exist to show if cardiorespiratory ﬁtness is related to the risk 
of sudden cardiac death. This study was conducted to show the prognostic value of 
cardiorespiratory ﬁtness with mortality from sudden cardiac death in a population-based 
sample of men.
Methods: We explored the possibility that low cardiorespiratory ﬁtness may indeed 
precede clinical symptoms and allow early identiﬁcation of persons at increased risk for 
sudden cardiac death in a random population based sample of 2368 men (age 42 to 
60 years). Maximal oxygen consumption (VO2max, mL per kg in minute) was measured 
directly by using respiratory gas exchange in a cycle exercise test. There were 146 
sudden cardiac deaths within 24 hours from symptoms during the 17 year follow-up.
Results: A total of 123 sudden cardiac deaths (84.2 %) occurred out-hospital conditions, 
and 105 (71.9 %) of these out-hospital deaths were due to documented ventricular 
tachycardia or ﬁbrillation. One metabolic equivalent (MET, 3.5 mL per kg in minute) 
increment in VO2max was related a decreased risk of sudden cardiac death (hazard ratio 
0.78, 95 % CI, 0.71-0.84, p<0.001). The risk of sudden cardiac death decreased 20 % 
in healthy and 25 % in unhealthy men including those with previous CVD per one MET 
increment in VO2max, respectively. The multivariable adjusted risk of sudden cardiac death 
was increased (hazard ratio 2.58, 95 % CI 1.45 to 4.58, p=0.001) among men in the lowest 
tertile of VO2max (<26.8 mL/kg/minute, 789 men) as compared to those in the highest tertile 
of VO2max (>33.2 mL/kg/minute, 789 men). VO2max, ischemic ST-depression during exercise 
testing, smoking, systolic blood pressure, history of coronary heart disease, family history 
of coronary heart disease and type II diabetes represented strongest independent risk 
predictors for sudden cardiac death.
Conclusions: Our study shows an inverse dose-response relationship between 
cardiorespiratory ﬁtness and sudden cardiac death. Cardiorespiratory ﬁtness is as a very 
powerful predictor of sudden cardiac death beyond that predicted by many conventional 
risk factors.
